Drug safety, prescription drug abuse, value of prescription drugs; Issues related to drug pricing, including orphan drugs
2026 · 2nd Quarter (Apr 1 - June 30)
JAZZ PHARMACEUTICALS, INC.
Filed by AVENUE SOLUTIONS.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 20, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- AVENUE SOLUTIONS
- Filing UUID
- e6a67197-87fc-4c77-aa53-4081877229c4
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to implementation of the Inflation Reduction Act of 2022; Issues related to Senate Finance Dear Colleague process; H.R. 946/S. 1862, ORPHAN Cures Act
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.